As filed with the Securities and Exchange Commission on July 28, 2016December 4, 2019

No. 333-212439333- _______

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1 to

FORMS-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

PIERIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

255 State Street, 9^th Floor

Boston, MA 02109

United States

(857) 246-89981-857-246-8998

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

StephenAhmed S. YoderMousa

General Counsel

255 State Street, 9^th Floor

Boston, MA 02109

United States

(857) 246-8998246-9889

(Name, address, including zip code, and telephone number, including, area code, of agent for service)

With copies to:

William C. Hicks, Esq.

Marc D. Mantell, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

(617)542-6000

Approximate date of commencement of proposed sale to the public:From time to time after the effective date of this registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ¨box:  ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  xbox:  ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ¨☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” andfiler,” “smaller reporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.  ☐

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with SectionCALCULATION OF REGISTRATION FEE

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) of the Securities Act ofOF THE SECURITIES ACT OF 1933, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said SectionAS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), may determine.MAY DETERMINE.

On July 8, 2016, Pieris Pharmaceuticals, Inc. (the “Company”) filed a registration statement with the Securities and Exchange Commission (the “SEC”) on Form S-3 (File No. 333-212439) (the “Registration Statement”) to register an aggregate of 13,102,084 shares of the Company’s common stock, par value $0.001 per share, for resale by certain selling stockholders identified in the prospectus to the Registration Statement. This Amendment No. 1 to the Registration Statement (“Amendment No. 1”) is being filed prior to the effectiveness of the Registration Statement and pursuant to the undertakings in Item 17 of the Registration Statement to update and supplement the information contained in the Registration Statement (i) to include the information contained in Amendment No. 2 to the Company’s Annual Report on Form 10-K which was filed with the SEC on July 20, 2016, (ii) to include the information contained in Amendment No. 1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016 which was filed with the SEC on July 20, 2016, (iii) to include the information contained in the Company’s Current Report on Form 8-K which was filed with the SEC on July 26, 2016 and (iv) to include an updated prospectus relating to the offering and sale of the shares that are being registered for resale on the Form S-3.

No additional securities are being registered under this Amendment No. 1. All applicable registration fees were paid at the time of the original filing of the Registration Statement.

The information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED July 28, 2016DECEMBER 4, 2019

PROSPECTUS

PIERIS PHARMACEUTICALS, INC.

13,102,084

18,029,920 Shares of Common Stock

This prospectus relates to the offering and resale by theThe selling stockholders of Pieris Pharmaceuticals, Inc. (“Pieris,” “we,” “us” or the “Company”) identified herein,in this prospectus, including their pledgees, donees, transferees, pledgeesassigns or donees, or their respectiveother successors ofin interest, may offer and resell under this prospectus up to 13,102,084shares18,029,920 shares of common stock, par value $0.001 per share, of Pieris Pharmaceuticals, Inc. Of the Company (the “Common Stock”). The number of shares being offered for sale by the selling stockholders consists of (i) 3,225,804 are5,492,960 shares of Common Stock (the “Common Shares”) presently issued and outstanding, (ii) 4,963,000 are3,522,000 shares of Common Stock (the “Underlying Shares”) issuable upon the conversion of 4,9633,522 shares of ourthe Company’s Series AC Convertible Preferred Stock, par value $0.001 per share or(the “Preferred Shares”), and (iii) 9,014,960 shares of Common Stock issuable upon the Series Aexercise of warrants (the “2019 PIPE Warrants”) to purchase Common Stock (the “Warrant Shares”, and together with the Underlying Shares and the Common Shares, the “Shares”). The Common Shares, the Preferred Shares and (iii) 4,913,280 are issuable upon exercise of common stock purchase warrants, or the PIPE Warrants. These shares and the2019 PIPE Warrants were sold to the selling stockholders, each of which is an accredited investorsinvestor, in a private placement offering whichtransaction that closed on June 8, 2016, orNovember 6, 2019 (the “2019 PIPE”).

We are registering the 2016 PIPE.resale of the Shares covered by this prospectus as required by the registration rights agreement we entered into with the selling stockholders on November 2, 2019 (the “2019 PIPE Registration Rights Agreement”). The selling stockholders will receive all of the proceeds from any sales of the Shares offered hereby. We will not receive any of the proceeds, but we will incur expenses in connection with the offering. To the extent the 2019 PIPE Warrants are exercised on a cash basis, if at all, we will receive the exercise price of the 2019 PIPE Warrants.

The selling stockholders may sell the shares of common stock on any national securities exchangeShares through public or quotation service on which the securities may be listed or quotedprivate transactions at the time of sale, in the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determinedprevailing at the time of sale or at negotiated prices. SeeThe timing and amount of any sale are within the disclosure under the heading “Plansole discretion of Distribution” elsewhere in this prospectus for more information about how the selling stockholders may sell or otherwise dispose of their shares of common stock hereunder.

stockholders. The selling stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the selling stockholders may sell their shares of common stockCommon Stock hereunder following the effective date of this registration statement.

We will Our registration of the Shares covered by this prospectus does not receive any proceeds from the sale of our common stock bymean that the selling stockholders inwill offer or sell any of the offering describedShares. For further information regarding the possible methods by which the Shares may be distributed, see “Plan of Distribution” in this prospectus.

Our common stock is listed on the NASDAQThe Nasdaq Capital Market under the symbol “PIRS”. On July 22, 2016,December 3, 2019, the last reported sale price for our common stock was $1.69$3.90 per share.

Investing in our common stock involves a high degree of risk. Before making any investment in our common stock, you should read andPlease consider carefully consider the risks described in this prospectus under “Risk Factors” beginning on page 65 of this prospectus.prospectus and in our filings with the Securities and Exchange Commission.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

This prospectus is dated            , 20162019

TABLE OF CONTENTS

i

About ABOUT THIS PROSPECTUS

This Prospectus

You should rely only on the informationprospectus is part of a registration statement that we have providedfiled with the Securities and Exchange Commission (the “SEC”) pursuant to which the selling stockholders named herein may, from time to time, offer and sell or incorporatedotherwise dispose of the Shares covered by reference in this prospectus, any applicable prospectus supplement and any related free writing prospectusprospectus. You should not assume that we may authorize to be provided to you. We have not authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give anythe information or to represent anything not contained in this prospectus any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as ofon any date subsequent to the date set forth on the front cover of the document andthis prospectus or that any information we have incorporated by reference is accurate only as ofcorrect on any date subsequent to the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security registered under the registration statement of whicheven though this prospectus is delivered or Shares are sold or otherwise disposed of on a part.later date.

This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the capital stock,Shares, you should refer to the registration statement including the exhibits. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find AdditionalMore Information.” We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under “Where You Can Find More Information” and “Incorporation of Certain Documents by Reference” in this prospectus.

We and the selling stockholders have not authorized anyone to give any information or to make any representation to you other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our shares of Common Stock other than the Shares covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about, and to observe, any restrictions as to the offering and the distribution of this prospectus applicable to those jurisdictions.

This prospectus, including the documents incorporated by reference herein, include statements that are based on various assumptions and estimates that are subject to numerous known and unknown risks and uncertainties. Some of these risks and uncertainties are described in the section entitled “Risk Factors” beginning on page 5 of this prospectus and described in described in Part I, Item 1A (Risk Factors) of our most recent Annual Report onForm 10-K for the fiscal year ended December 31, 2018, or our Annual Report, as well as the other documents that we file with the SEC. These and other important factors could cause our future results to be materially different from the results expected as a result of, or implied by, these assumptions and estimates. You should read the information contained in, or incorporated by reference into, this prospectus completely and with the understanding that future results may be materially different from and worse than what we expect. See the information included under the heading “Special Note Regarding Forward-Looking Statements.”

As used in this prospectus, unless the context indicates or otherwise requires, “our Company”, “the Company”, “Pieris”, “we”,references in this prospectus to “Pieris,” the “Company,” “we,” “us”, and “our” refer to Pieris Pharmaceuticals, Inc., a Nevada corporation, and itsour consolidated subsidiary, and the term “Pieris GmbH” refers to Pieris Pharmaceuticals GmbH, a company organized under the laws of Germany that, through a share exchange transaction completed on December 17, 2014, has become our wholly owned subsidiary.subsidiaries.

We have registered trademarks for Pieris^®, and Anticalin^® and Pocket Binding^®. All other trademarks, trade names and service marks included in this prospectus are the property of their respective owners. Use or display by us of other parties’ trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owner.

ii

RISK FACTORS

Investing in our common stockCommon Stock involves a high degree of risk. You should carefully consider the risks and uncertainties and all other information, documents or reports included or incorporated by reference in this prospectus and, if applicable, any prospectus supplement or other offering materials, including the risks and uncertainties discussed under Item 1A, “Risk Factors”Factors,” in our most recent Annual Report on Form10-K for the fiscal year ended December 31, 2018 filed with the SEC on March 18, 2019, as updated by our subsequent filings with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are incorporated by reference, in this prospectus, and any updates to those risk factors included from time to time in our periodic and current reports filed with the SEC and incorporated by reference in this prospectus, before making any decision to invest in shares of our common stock.Common Stock. If any of the events discussed in these risk factors occurs, our business, prospects, results of operations, financial condition and cash flows could be materially harmed. If that were to happen, the trading price of our common stockCommon Stock could decline, and you could lose all or part of your investment. Additional risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus and the documents we have filed with the SEC that are incorporated by reference in this prospectus include forward-looking statementscontain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act that involve substantial risks and uncertainties. In some cases, forward-looking statements are identified by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “goals,” “intend,” “likely,” “may,” “might,” “ongoing,” “objective,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “will” and “would” or the negative of 1934, as amended, includingthese terms, or other comparable terminology intended to identify statements regarding:about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus and the documents that we have filed with the SEC that are incorporated by reference, such statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about:

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such statementsfactors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in connection withour studies; our ability to address the requests of the FDA; competition in the industry in which we operate; the timing and nature of data from the phase 2a study ofPRS-060/AZD1402; whether or not Pieris opts-intoco-development ofPRS-060/AZD1402; whether or not any discussion of future operations or financial performance are identified bythe warrants issued in the private placement will be exercised for cash; the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “target,” “potential,” “shall,” “will,” “would,” “could,” “should,” “continue,”any proceeds from any warrant exercise; and similar expressions.market conditions. You also can identify them byshould refer to the factsection titled “Risk Factors” of this prospectus and in our other filings with the SEC, including our Annual Report on Form10-K for the year ended December 31, 2018, for further discussion of the important factors that they do not relate strictly to historical or current facts. There are a number of important risks and uncertainties that couldmay cause our actual results to differ materially from the results discussed in the forward-looking statements.

We may not actually achieve the plans, intentionsthose expressed or expectations disclosed in our forward-looking statements, and you should not place undue reliance onimplied by our forward-looking statements. Actual results or events could differ materially fromAs a result of these factors, we cannot assure that the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important cautionary statements in this prospectus or in the documents incorporated by reference in this prospectus, particularly in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. For a summary of such factors, please refer to the section entitled “Risk Factors” in this prospectus, as updated and supplemented by the discussion of risks and uncertainties under “Risk Factors” contained in our most recent annual report on Form 10-K, as revised or supplemented by our subsequent quarterly reports on Form 10-Q or our current reports on Form 8-K, as well as any amendments thereto, ashave filed with the SEC and whichthat are incorporated herein by reference. The information contained in this document is believedreference will prove to be currentaccurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as representations or warranties by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this document.prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements as predictions of future events.

You should read this prospectus, the underlying prospectus, the documents that we have incorporated by reference herein and the documents we have filed as exhibits to the registration statement, completely and with the understanding that our actual future results may be materially different from what we expect. We do not undertake any obligation or intend to update anyqualify all of theour forward-looking statements after the date of this document to conformby these statements to actual results or to changes in our expectations, except as required by law.cautionary statements.

USE OF PROCEEDS

We will not receive any proceeds from the sale of the Shares offered pursuant to this prospectus. The selling stockholders will receive all of the proceeds from the sale of securitiesthe Shares offered by this prospectus. For information about the selling stockholders, see the section titled “Selling Stockholders” included in this prospectus. The selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling security holders pursuantstockholders in disposing of the shares, except we have agreed to reimburse up to an aggregate of $25,000 of fees and expenses of counsel for the selling stockholders. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus.prospectus, including all registration and filing fees and fees and expenses of our counsel and accountants. We may receive up to approximately $11,464,320$64,006,216 in aggregate gross proceeds from cash exercises of the 2019 PIPE Warrants, based on the per share exercise price of the warrants.warrants, in the event any of the 2019 PIPE Warrants are exercised on a cash basis. Any proceeds we receive from the exercise of the warrants will be used for researchour proprietary and development,partnered drug candidates and may be used in particular to facilitate Pieris’ potentialopt-into theco-development ofPRS-060/AZD1402 in the event of positive Phase 2a data. Any proceeds we receive from the exercise of the 2019 PIPE Warrants may also be used for working capital and general corporate purposes.

SELLING STOCKHOLDERS

This prospectus covers the resale from time to time by the selling stockholders identified in the table below, including their pledgees, donees, transferees, assigns or other successors in interest, of up to an aggregate of 13,102,08418,029,920 shares of our common stock,Common Stock, which includes (i) 3,225,8045,492,960 issued and outstanding shares of our common stock,Common Shares, (ii) 4,963,000 shares of our common stock issuable3,522,000 Underlying Shares upon the conversion of 4,963 Series A3,522 Preferred Shares and (iii) 4,913,2809,014,960 shares of our common stockCommon Stock issuable upon exercise of the 2019 PIPE Warrants, all of which were issued in connection with the 20162019 PIPE.

Pursuant to the registration rights agreement we entered into with the selling stockholders in connection with the 2016 PIPE, or the 20162019 PIPE Registration Rights Agreement, we have filed with the SEC the registration statement of which this prospectus forms a part in order to register such resales of our common stockCommon Stock under the Securities Act. We have also agreed to cause this registration statement to become effective and to keep such registration statement effective within and for the time periods set forth in the 20162019 PIPE Registration Rights Agreement. Our failure to satisfy the filing or effectiveness deadlines set forth in the 20162019 PIPE Registration Rights Agreement may subject us to payment of certain monetary penalties pursuant to the terms of the 20162019 PIPE Registration Rights Agreement.

The selling stockholders identified in the table below may from time to time offer and sell under this prospectus any or all of the shares of common stockCommon Stock described under the column “Shares“Number of Shares of Common Stock Being Offered in this Offering”Offered” in the table below. The table below has been prepared based upon information furnished to us by the selling stockholders as of the dates represented in the footnotes accompanying the table. The selling stockholders identified below may have sold, transferred or otherwise disposed of some or all of their shares since the date on which the information in the following table is presented in transactions exempt from or not subject to the registration requirements of the Securities Act. Information concerning the selling stockholders may change from time to time and, if necessary, we will amend or supplement this prospectus accordingly and as required.

We have been advised, as noted in the footnotes in the table below, that certain of the selling stockholders are broker-dealers, affiliates of a broker-dealer and/or underwriter. Those selling stockholders have informed us that they bought our securities in the ordinary course of business, and that none of these selling stockholders had, at the time of their purchase of our securities, any agreements or understandings, directly or indirectly, with any person to distribute such securities.

The following table and footnote disclosure following the table sets forth the name of each selling stockholder, the nature of any position, office or other material relationship, if any, that the selling stockholder hasstockholders have had within the past three years with us or with any of our predecessors or affiliates, and the number of shares of our common stockCommon Stock beneficially owned by the selling stockholderstockholders before this offering. The number of shares reflected are those beneficially owned, as determined under applicable rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under applicable SEC rules, beneficial ownership includes any shares of common stockCommon Stock as to which a person has sole or shared voting power or investment power and any shares of common stockCommon Stock which the person has the right to acquire within 60 days after July 22, 2016November 7, 2019 through the exercise of any option, warrant or right or through the conversion of any convertible security. Unless otherwise indicated in the footnotes to the table below and subject to community property laws where applicable, we believe, based on information furnished to us that each of the selling stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned.

Unless otherwise indicated in the footnotes to the table below and subject to community property laws where applicable, we believe, based on information furnished to us that each of the selling stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned.

We have assumed that all shares of common stockCommon Stock reflected in the table as being offered in the offering covered by this prospectus will be sold from time to time in this offering. We cannot provide an estimate as to the number of shares of common stockCommon Stock that will be held by the selling stockholders upon termination of the offering covered by this prospectus because the selling stockholders may offer some, all or none of their shares of common stockCommon Stock being offered in the offering. Information about the selling stockholders may change over time. Any changed information will be set forth in an amendment to the registration statement or supplement to this prospectus, to the extent required by law.

Exchange Act, more than 9.99% of the number of shares of our common stockCommon Stock then issued and outstanding. BVF Partners, L.P., or Partners, is the general partner of the selling stockholder and along with BVF Inc., its general partner, may be deemed to beneficially own these shares. Mr. Mark N. Lampert, as a director and officer of BVF Inc., may also be deemed to beneficially own these securities. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interests therein.

(6)(5)

Includes (i) 1,401,0001,021,000 shares of common stockour Common Stock issuable upon the conversion of 1,4011,021 Series A Preferred Shares, (ii) 2,143,000 shares of our Common Stock issuable upon the conversion of 2,143 Series B Preferred Shares, (iii) 1,445,000 shares of Common Stock issuable upon the conversion of 1,445 Series C Preferred Shares, and (ii)(iv) warrants to purchase 840,6002,285,600 shares of our common stock.Common Stock. The Series A, Series B, and Series C Preferred Shares held by the selling stockholder and warrants held by the selling stockholder may not be converted if, after such conversion, the selling stockholder and its affiliated entities would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of our common stockCommon Stock then issued and outstanding. Partners is the general partner of the selling stockholder and along with BVF Inc., its general partner, may be deemed to beneficially own these securities. Mr. Mark M. Lampert, as a director and officer of BVF Inc., may also be deemed to beneficially own these shares. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interests therein.

(7)(6)

Includes (i) 419,000319,000 shares of common stockour Common Stock issuable upon the conversion of 419319 Series A Preferred Shares, (ii) 284,000 shares of our Common Stock issuable upon the conversion of 284 Series B Preferred Shares, (iii) 265,000 shares of our Common Stock issuable upon the conversion of 265 Series C Preferred Shares, and (ii)(iv) warrants to purchase 251,400516,400 shares of our common stock.Common Stock. The Series A, Series B, and Series C Preferred Shares held by the selling stockholder and warrants held by the selling stockholder may not be converted if, after such conversion, the selling stockholder and its affiliated entities would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of our common stockCommon Stock then issued and outstanding. BVF Partners OS Ltd., or Partners OS, is the general partner of Biotechnology Value Trading Fund OS, L.P., or Trading Fund OS,the selling stockholder, and along with Partners, its sole member and the investment manager of Trading Fund OS,the selling stockholder, and BVF Inc., the general partner of Partners, may be deemed to beneficially own these shares. Mr. Mark M. Lampert, as a director and officer of BVF Inc., may also be deemed to beneficially own these securities. Each of Partners OS, Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interests therein.

(12)	Includes warrants to purchase 133,995 shares of our common stock. Joshua Scheinfeld and Jonathan Cope, the principals of the selling stockholder, share voting and dispositive power over these securities and may be deemed to be their beneficial owners.

(13)

Includes (i) 661,000 shares of common stock issuable upon the conversion of 661 Series A Preferred Shares and (ii) warrants to purchase 396,600 shares of our common stock. The Series A Preferred Shares held by the selling stockholder may not be converted if, after such conversion, the selling stockholder and its affiliated entities would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of our common stockCommon Stock then issued and outstanding. Partners asis the investment advisormanager of MSIthe selling stockholder, and BVF SPV, L.L.C.Inc., itsthe general partner BVF Inc., andof Partners, may be deemed to beneficially own these shares. Mr. Mark M. Lampert, as a director and officer of BVF Inc., may also be deemed to beneficially own these securitiessecurities. Each of Partners, BVF Inc. and eachMr. Lampert disclaims beneficial ownership with respect to these securities other than with respect to their pecuniary interests therein.

(14)

Includes warrants to purchase 595,533 shares of our common stock. Sabby Management LLC, the investment advisor of the selling stockholder and its manager, Mr. Hal Mintz, hold voting and dispositive power of these securities and may be deemed to be their beneficial owners but disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein.

(8)

Includes: (i) 2,110,310 shares of our Common Stock, and (ii) warrants exercisable for 2,110,310 shares of our Common Stock (the “EcoR1 Qualified Warrants”). The warrants held by the selling stockholderEcoR1 Qualified Warrants may not be convertedexercised if, after such conversion, the selling stockholderexercise, EcoR1 Capital Fund Qualified, L.P. (“EcoR1 Qualified”) and its affiliated entities would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 4.99%9.99% of the number of shares of our common stockCommon Stock then issued and outstanding. EcoR1 Qualified is managed by EcoR1 Capital, LLC, which is managed by Oleg Nodelman. The selling stockholder also holds 127,159 sharesaddress of common stock which were not purchased as part of the 2016 PIPE.EcoR1 Qualified is 357 Tehama Street, #3, San Francisco, CA 94103.

(15)(9)

Includes warrants to purchase 297,767 Includes: (i) 424,902 shares of our common stock. Sabby Management LLC, the investment advisorCommon Stock and (ii) warrants exercisable for 424,902 shares of the selling stockholder and its manager, Mr. Hal Mintz, hold voting and dispositive power of these securities and may be deemed to be their beneficial owners but disclaim beneficial ownership of such securities, except to the extent of their pecuniary interests therein.our Common Stock (the “EcoR1 Capital Warrants”). The warrants held by the selling stockholderEcoR1 Capital Warrants may not be convertedexercised if, after such conversion, the selling stockholderexercise, EcoR1 Capital Fund, L.P. (“EcoR1 Capital Fund”) and its affiliated entities would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 4.99%9.99% of the number of shares of our common stockCommon Stock then issued and outstanding. EcoR1 Capital Fund is managed by EcoR1 Capital, LLC, which is managed by Oleg Nodelman. The address of EcoR1 Capital Fund is 357 Tehama Street, #3, San Francisco, CA 94103.

(16)(10)

Includes warrants to purchase 35,732 Includes: (i) 3,670,563 shares of our common stock. EachCommon Stock, including 1,126,761 shares of Mr. Daniel R. Ornstead, through his controlour Common Stock purchased in the 2019 PIPE, and (ii) warrants exercisable for 1,126,761 shares of Teklaour Common Stock (the “Aquilo Warrants”). The Aquilo Warrants may not be exercised if, after such exercise, Aquilo Capital, L.P. and its affiliated entities would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of our Common Stock then issued and outstanding. The address of Aquilo is c/o Aquilo Capital Management, LLC, or TCM,One Letterman Drive, Suite D4900, San Francisco, CA 94129.

(11)

Includes (i) 1,126,761 shares of our Common Stock and TCM(ii) warrants exercisable for 1,126,761 shares of our Common Stock (the “Surveyor Warrants”). The Surveyor Warrants may not be exercised if, after such exercise, Citadel Multi-Strategy Equities Master Fund Ltd. (“Citadel”) and its affiliated entities would beneficially own, as a result of acting as investment adviser to the selling stockholder, which is registered as an investment company pursuant todetermined in accordance with Section 813(d) of the Investment CompanyExchange Act, more than 9.99% of 1940,the number of shares of our Common Stock then issued and outstanding. Citadel Advisors LLC (“Citadel Advisors”), acts as the portfolio manager of Citadel. Citadel Advisors Holdings LP (“CAH”) is the sole member of Citadel Advisors. Citadel GP LLC (“CGP”) is the general partner of CAH. Mr. Kenneth Griffin is the President and Chief Executive Officer of CGP and owns a controlling interest in CGP and may be deemed to be the beneficial owner of these securities but disclaim beneficial ownership, except to the extent of their pecuniary interests therein.share voting and dispositive power over shares held by Citadel. The selling stockholder also holds 769,638address for this entity is c/o Citadel Advisors LLC, 601 Lexington Avenue, New York, NY 10022.

(12)	Includes (i) 704,226 shares of our common stock which were not purchased as part of the 2016 PIPE.

(17)

IncludesCommon Stock and (ii) warrants to purchase 82,184exercisable for 704,226 shares of our common stock. Each of Mr. Daniel R. Ornstead, through his control of Tekla Capital Management LLC, or TCM,Common Stock (the “Samsara Warrants”). The Samsara Warrants may not be exercised if, after such exercise, Samsara BioCapital, L.P. (“Samsara”) and TCMits affiliated entities would beneficially own, as a result of acting as investment adviser to the selling stockholder, which is registered as an investment company pursuant todetermined in accordance with Section 813(d) of the Investment CompanyExchange Act, more than 9.99% of 1940, may be deemed to be the beneficial ownernumber of these securities but disclaim beneficial ownership, except to the extent of their pecuniary interests therein. The selling stockholder also holds 1,770,168 shares of our common stock which were not purchased as part of the 2016 PIPE.

(18)

Includes warrants to purchase 60,744 shares of our common stock. Each of Mr. Daniel R. Ornstead, through his control of TCM,Common Stock then issued and TCM as a result of acting as investment adviseroutstanding. Srinivas Akkaraju, MD, Ph.D. has sole voting and dispositive power with respect to the selling stockholder, whichsecurities held by Samsara. The address of Samsara is registered as an investment company pursuant to Section 8 of the Investment Company Act of 1940, may be deemed to be the beneficial owner of these securities but disclaim beneficial ownership, except to the extent of their pecuniary interests therein. The selling stockholder also holds 1,308,385 shares of our common stock which were not purchased as part of the 2016 PIPE.628 Middlefield Road, Palo Alto, CA 94301.

PLAN OF DISTRIBUTION

We are registering the shares of common stock issued toCommon Shares, the selling stockholdersUnderlying Shares and issuable upon exercise of the warrantsWarrant Shares issued to the selling stockholders to permit the resale of these shares of common stockCommon Stock by the holders of the shares of common stockCommon Stock and warrants from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock.Common Stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.Common Stock.

The selling stockholders may sell all or a portion of the shares of common stockCommon Stock beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of common stockCommon Stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of common stock may be sold in one or more transactions, which may involve crosses or block transactions, andCommon Stock may be sold on any national securities exchange or quotation service on which our common stockthe securities may be listed or quoted at the time of sale, in theover-the-counter market or in transactions otherwise than on these exchanges or systems or in theover-the-counter market and in one or more market transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The selling stockholders may use any one or more of the following methods when selling shares:

The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, as permitted by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions.

Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. If the selling stockholders effect such transactions by selling shares of common stockCommon Stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the shares of common stockShares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus,Prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.01.

In connection with sales of the shares of common stockShares or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stockShares in the course of hedging in positions they assume. The selling stockholders may also sell shares of common stockShares short and if such short sale shall take place after the date that this registration statementRegistration Statement is declared effective by the SEC,Commission, the selling stockholders may deliver shares of common stockShares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares of common stockShares to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the selling stockholders have been advised that they may not use shares registered pursuant toon this registration statement to cover short sales of our common stockCommon Stock made prior to the date the registration statement, of which this prospectus forms a part, ishas been declared effective by the SEC.

The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the warrants2019 PIPE Warrants or shares of common stockShares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stockCommon Stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended, amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the shares of common stockCommon Stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

The selling stockholders and any broker-dealer or agents participating in the distribution of the shares of common stock offered herebyShares may be deemed to be “underwriters” within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling stockholdersStockholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act andRule 10b-5 under the Securities Exchange Act of 1934, as amended, or the Exchange Act.

Each selling stockholder has informed usthe Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the common stock.Common Stock. Upon usthe Company being notified in writing by a selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of common stockour Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker-dealer,broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such the shares of common stockCommon Stock were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi) other facts material to the transaction.

Under the securities laws of some states, the shares of common stockShares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of common stockShares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.

There can be no assurance that any selling stockholder will sell any or all of the shares of common stockShares registered pursuant to the shelf registration statement, of which this prospectus forms a part.

Each selling stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of common stockShares by the selling stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stockCommon Stock to engage in market-making activities with respect to the shares of common stock.Common Stock. All of the foregoing may affect the marketability of the shares of common stockCommon Stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock.Common Stock.

We will pay all expenses of the registration of the shares of common stockCommon Stock pursuant to the 2016 PIPE Registration Rights Agreement,registration rights agreement, including, without limitation, SECSecurities and Exchange Commission filing fees and expenses of compliance with state securities or “blue sky” laws;provided,however, that each selling stockholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. it; provided further that we have agreed to reimburse up to $25,000 of fees and expenses of counsel for the selling stockholders. We may receive up to approximately $64,006,216 in aggregate gross proceeds from cash exercises of the 2019 PIPE Warrants, based on the per share exercise price of the warrants, in the event any of the 2019 PIPE Warrants are exercised on a cash basis. Any proceeds we receive from the exercise of the warrants will be used for our proprietary and partnered drug candidates and may be used in particular to facilitate Pieris’ potentialopt-into theco-development ofPRS-060/AZD1402 in the event of positive Phase 2a data. Any proceeds we receive from the exercise of the 2019 PIPE Warrants may also be used for working capital and general corporate purposes.

We will indemnify the selling stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the 2016 PIPE Registration Rights Agreement,registration rights agreement, or the selling stockholders will be entitled to contribution. We may be indemnified by the selling stockholders against civil liabilities, including liabilities under the Securities Act, that may arise from any written information furnished to us by the selling stockholders specifically for use in this prospectus, in accordance with the 2016 Private Placement Registration Rights Agreement,related registration rights agreements, or we may be entitled to contribution.

LEGAL MATTERS

The validity of the common stock being offered by this prospectus is being passed upon by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

EXPERTS

The consolidated financial statements of Pieris Pharmaceuticals, IncInc. appearing in Pieris Pharmaceuticals, Inc.’s Annual Report (Form10-K), as amended, at December 31, 2015 and 2014, and for each of the two years in the periodyear ended December 31, 2015,2018, have been audited by Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft,LLP, independent registered public accounting firm, as set forth in their report thereon, incorporated by referenceincluded therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reportsreport given on the authority of such firm as experts in accounting and auditing.

WHERE YOU CAN FIND ADDITIONALMORE INFORMATION

We are subject to the reporting requirements of the Securities Exchange Act, of 1934, as amended, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You may readThe SEC maintains an internet website at www.sec.gov that contains periodic and copy thesecurrent reports, proxy and information statements, and other information atregarding registrants that are filed electronically with the SEC’s public reference facilities at 100 F Street, N.E., Room 1580, Washington, D.C. 20549.SEC. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the public reference facilities. SEC filings are also available at the SEC’s web site at http://www.sec.gov.

This prospectus is only part of a registration statement on FormS-3 that we have filed with the SEC under the Securities Act of 1933, as amended, and therefore omits certain information contained in the registration statement. We have also filed exhibits and schedules with the registration statement that are excluded from this prospectus, and you should refer to the applicable exhibit or schedule for a complete description of any statement referring to any contract or other document. You may inspectobtain a copy of the registration statement, including the exhibits and schedules, without charge, at the public reference room or obtain a copy from the SEC upon payment of the fees prescribed by the SEC.SEC’s website.

We also maintain a website athttp://www.pieris.com, through which you can access our SEC filings.filings free of charge. The information set forth on our website is not part of this prospectus.

INFORMATION INCORPORATEDINCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The SEC allows us to “incorporate by reference” information into this prospectus, informationwhich means that we have filed with the SEC. This means we can disclose important information to you by referring you to other documents that contain that information.another document filed separately with the SEC. The information incorporated by reference is considereddeemed to be part of this prospectus, and subsequent information that we file later with the SEC will automatically update and supersede this information. We filed a registration statement on FormS-3 under the Securities Act with the SEC with respect to the securities we may offer pursuant to this prospectus. We incorporateThis prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities we may offer pursuant to this prospectus. Statements in this prospectus regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the registration statement, including the documents listed below:incorporated by reference or the exhibits, may be obtained from the SEC’s website at http://www.sec.gov. The documents we are incorporating by reference are:

The SEC file number for each of the documents listed above is001-37471.

Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statementsstatement so modified or superseded shallwill not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

You may request, a copy of these documents, orally or in writing, whicha copy of any or all of the documents incorporated herein by reference. These documents will be provided to you at no cost, by contacting:

Pieris Pharmaceuticals, Inc.

255 State Street, 9^th Floor

Boston, MassachusettsMA 02109, USA

Attention:Attn: Investor Relations

Telephone: +1 (857)246-8998

You may also access these documents on our website,http://www.pieris.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

You should rely only on information contained in, or incorporated by reference into, this prospectus. We and the selling stockholders have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference in this prospectus. We and the selling stockholders are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.

18,029,920 Shares

Common Stock

PROSPECTUS

, 2019

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14. Other Expenses of Issuance and Distribution.

Set forth below is an estimate (except for registration fees, which are actual) of the approximate amount of the types of fees and expenses listed below that were paid or are payable by us in connection with the issuance and distribution of the shares of common stock to be registered by this registration statement. None of the expenses listed below are to be borne by any of the selling stockholders named in the prospectus that forms a part of this registration statement.

We are a Nevada corporation and are generally governed by the Nevada Revised Statutes, our amended and restated articles of incorporation, amended and restated bylaws or NRS.any separate agreement may provide for our payment of expenses incurred by any such director or officer in advance of the final disposition of the applicable action, suit or proceeding, upon delivery by such director or officer of an undertaking to repay all amounts so advanced if it is ultimately determined that the director or officer is not entitled to be indemnified by us.

Our amended and restated articles of incorporation provide for indemnification of our directors and ourofficers substantially identical in scope to that permitted under applicable Nevada law. Our amended and restated bylawsarticles of incorporation also provide that the expenses of our directors and officers incurred in defending any applicable action, suit or proceeding must be paid by us as they are incurred and in advance of the final disposition of the action, suit or proceeding, provided that the required undertaking by the director or officer is delivered to us.

We have also entered into separate indemnification agreements with each of our current directors and executive officers consistent with Nevada law and in the form approved by our Board of Directors and our stockholders, and we contemplate entering into such indemnification agreements with directors and certain executive officers that may be elected or appointed in the future. Those indemnification agreements require that under the circumstances and to the extent provided for therein, we indemnify such persons to the fullest extent permitted by applicable law against certain expenses incurred by any such person who was or is madeas a party or is threatened to beresult of such person being made a party to or is otherwise involved (including, without limitation, as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was one of our directors or officers or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, whether the basis of such action, suit or proceeding is alleged action in an official capacity as a director, officer or trustee or in any other capacity while serving as a director, officer or trustee, shall be indemnifiedcertain actions, suits and held harmless by us to the fullest extent authorized by NRS against all expense, liability and loss (including attorneys’ fees and amounts paid in settlement) reasonably incurred or suffered by such.

NRS 78.7502 permits a corporation to indemnify any director or officer of the corporation against expenses (including attorneys’ fees) and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding broughtproceedings by reason of the fact that such person is or was a director, officer, employee or officeragent of our company, any entity that was a predecessor corporation of our company or any of our affiliates. The rights of each person who is a party to such an indemnification agreement are in addition to any other rights such person may have under applicable Nevada law, our amended and restated articles of incorporation, our amended and restated bylaws, any other agreement, a vote of our stockholders, a resolution adopted by our Board of Directors or otherwise. The foregoing is only a brief description of the corporation, if such person (i) isform of indemnification agreement, does not liable pursuant to NRS 78.138 and (ii) acted in good faith and in a manner which he or she reasonably believedpurport to be a complete description of the rights and obligations of the parties thereunder and is qualified in or not opposedits entirety by reference to the best interestsform of indemnification agreement filed as an exhibit to the corporation,registration statement of which this prospectus forms a part and with respect to any criminal action or proceeding, had no reasonable cause to believeincorporated herein by reference.

We also maintain a customary insurance policy that indemnifies our directors and officers against various liabilities, including liabilities arising under the conduct was unlawful. In a derivative action (i.e., one brought by or on behalf of the corporation), indemnificationSecurities Act that may be provided only for expenses actually and reasonably incurred by any director or officer in connection with the defense or settlement of such an action or the suit if such person (i) is not liable pursuant to NRS 78.138 and (ii) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought or some other court of competent jurisdiction determines that such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

Our amended and restated Articles of incorporation provide that the liability of our directors and officers shall be eliminated or limited to the fullest extent permitted by the NRS. NRS 78.138(7) provides that, subject to limited statutory exceptions and unless the articles of incorporation or an amendment thereto (in each case filed on or

II-1

after October 1, 2003) provide for greater individual liability, a director or officer is not individually liable to a corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a directorsuch.

At present, there is no pending litigation or officer unless itproceeding involving any of our directors or officers for which indemnification is proven that: (i)sought, nor are we aware of any threatened litigation that is likely to result in claims for indemnification.

Any underwriting agreements that we may enter into will likely provide for the act or failure to act constituted a breachindemnification of his or her fiduciary duties as a director or officer and (ii) the breach of those duties involved intentional misconduct, fraud or a knowing violation of law.

We have entered into indemnification agreements withus, our controlling persons, our directors and certain officers, in addition to the indemnification provided in the NRS, our amended and restated articles of incorporation and our amended and restated bylaws, and intend to enter into indemnification agreements with any new directors and officers in the future. We have purchased and intend to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

The foregoing discussion of our amended and restated articlesofficers by the underwriters against certain liabilities, including liabilities under the Securities Act of incorporation, amended and restated bylaws, indemnification agreements, indemnity agreement, and Nevada law is not intended to be exhaustive and is qualified in its entirety by such amended and restated articles of incorporation, amended and restated bylaws, indemnification agreements, indemnity agreement, or law.1933, as amended.

Item 16. Exhibits and Financial Statements Schedules.

The exhibits to this registration statement are listed in the Exhibit Index immediately followingprior the signature page hereto, which areExhibit Index is hereby incorporated by reference into this Item 16 by reference.

Item 17. Undertakings.

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

provided, however,, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Sectionsection 13 or Sectionsection 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to be the initial

EXHIBIT INDEX

II-2

(3) To remove from registration by means of a post-effective amendment any of the securities being registered that remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A (§ 230.430A of Title 17 of the Code of Federal Regulations), shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (§230.424 of Title 17 of the Code of Federal Regulations);

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(6) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II-3

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for fillingfiling on FormS-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on July 28, 2016.December 4, 2019.

SIGNATURES AND POWER OF ATTORNEY

We, the undersigned officers and directors of Pieris Pharmaceuticals, Inc., hereby severally constitute and appoint Stephen S. Yoder and Thomas Bures and each of them singly (with full power to each of them to act alone), our true and lawfulattorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including, without limitation, post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto saidattorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that saidattorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

EXHIBIT INDEX